Guanfacine to Treat Borderline Personality Disorder - Full Text View

Sponsor:	Mount Sinai School of Medicine
Information provided by:	Bronx VA Medical Center
ClinicalTrials.gov Identifier:	NCT00358969

Purpose

This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.

Condition	Intervention
Borderline Personality Disorder	Drug: guanfacine (Tenex)

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Guanfacine in the Treatment of Borderline Personality Disorder

Resource links provided by NLM:

MedlinePlus related topics: Personality Disorders

Drug Information available for: Guanfacine Guanfacine hydrochloride

U.S. FDA Resources

Further study details as provided by Bronx VA Medical Center:

Primary Outcome Measures:

measures of impulsive aggression
measures of affective disturbance
measures of social and occupational functioning
measures of overall clinical status

Study Start Date:

July 2006

Detailed Description:

This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking the study medication, participants will meet weekly with a study doctor and be administered interviews and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the MRI scan and cognitive tests.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.

Exclusion Criteria: Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00358969

Contacts

Contact: Emily Hart	(212) 241-4459	mpgroup@mssm.edu
Contact: David Meyerson	(212) 241-9734	david.meyerson@mssm.edu

Locations

United States, New York
Mount Sinai Hospital - Mood & Personality Research Group	Recruiting
New York, New York, United States, 10029

Sponsors and Collaborators

Mount Sinai School of Medicine

Investigators

Principal Investigator:

Antonia S. New, M.D.

Mount Sinai School of Medicine

More Information

No publications provided

Study ID Numbers:	GCO 06-0518
Study First Received:	July 31, 2006
Last Updated:	July 31, 2006
ClinicalTrials.gov Identifier:	NCT00358969 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Bronx VA Medical Center:

borderline personality disorder
guanfacine
impulsivity
aggression
affective instability

Additional relevant MeSH terms:

Neurotransmitter Agents
Disease
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Borderline Personality Disorder

Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists
Pathologic Processes
Mental Disorders
Guanfacine
Therapeutic Uses
Personality Disorders

ClinicalTrials.gov processed this record on November 25, 2009